SciClone profit up 4.3% to RMB622.7m in H1 2021

Its revenue rose 14.7% to RMB1.3b in the same period. 

Hong Kong Exchange-listed SciClone Pharmaceuticals (Holdings) Limited posted a 4.3% increase in net profit attributable to shareholders to RMB622.7m in the first half of 2021 from RMB597b, in the same period last year.

Its revenue rose 14.7% in the first six months of the year to RMB1.3b, from RMB1.16b in the same period last year, it said in a disclosure to the bourse.

SciClone also posted a 9.9% increase in revenue from sales of its proprietary product Zadaxin to RMB1.1b during the period despite the high base of sales for the prevention and clinical treatment of COVID-19 in China in the same first half of 2020.

The Pharmaceuticals company also completed the transfer of import drug license for Zometa and became its marketing authorization holder in China in January, with revenue from the provinces wherein the registered distributor had been converted from Novartis to the company was RMB54.m.

“Leveraging our integrated platform, we have established a balanced product portfolio focusing on high potential therapeutic areas, led by marketed products with strong cash generation ability through effective lifecycle management, and supported by an innovative pipeline with first-in-class/best-in-class potential to drive sustainable long-term growth,” it said.

During the first half, among the development milestones reached by the company include the pilot launch of DANYELZA® (naxitamab) “for the treatment of patients with relapsed/refractory high-risk neuroblastoma in Hainan Bo’Ao Lecheng International Medical Tourism Pilot Zone in June.”

The National Medical Products Administration (NMPA) of China accepted its Biologics License Application for the said treatment in July, with the first prescription issued in early August.

It also submitted the investigation of new drugs application of RRx-001 Multi-Regional Clinical Trials Phase III study in the “third line and beyond small cell lung cancer in China to the NMPA which was approved in July, amongst others.